Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Cash Flow (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Net Cash Flow for 11 consecutive years, with -$39.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 157.91% to -$39.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$35.2 million, a 6.25% increase, with the full-year FY2025 number at -$35.2 million, up 6.25% from a year prior.
  • Net Cash Flow was -$39.8 million for Q4 2025 at Intellia Therapeutics, down from $37.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $385.7 million in Q4 2022 to a low of -$229.4 million in Q1 2023.
  • A 5-year average of $148100.0 and a median of -$8.6 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 1629.85% in 2023, then skyrocketed 459.45% in 2025.
  • Intellia Therapeutics' Net Cash Flow stood at -$211.5 million in 2021, then surged by 282.4% to $385.7 million in 2022, then crashed by 84.61% to $59.4 million in 2023, then rose by 15.7% to $68.7 million in 2024, then plummeted by 157.91% to -$39.8 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Net Cash Flow are -$39.8 million (Q4 2025), $37.2 million (Q3 2025), and $21.9 million (Q2 2025).